On July 30, 2025, Supernus Pharmaceuticals successfully completed its acquisition of Sage Therapeutics, purchasing shares at $8.50 each and offering contingent value rights potentially worth up to $234 million based on future sales milestones. The transaction was valued at approximately $561 million, following the tender offer which saw 58% of Sage's shares accepted.